Patents by Inventor Frank Bedu-Addo

Frank Bedu-Addo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210100898
    Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of argumenting an immune response in a mammal, and methods of treating a diseases in a mammal utilizing the vaccine compositions.
    Type: Application
    Filed: October 1, 2020
    Publication date: April 8, 2021
    Inventors: Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
  • Patent number: 10828364
    Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of argumenting an immune response in a mammal, and methods of treating a diseases in a mammal utilizing the vaccine compositions.
    Type: Grant
    Filed: March 28, 2019
    Date of Patent: November 10, 2020
    Assignees: PDS Biotechnology Corporation, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC. OF THE DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
  • Publication number: 20200330491
    Abstract: A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in R1 is a quaternary ammonium group, Y1 is a space chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, R2 and R3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combination thereof.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 22, 2020
    Inventors: Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya N. Toney Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
  • Patent number: 10702541
    Abstract: A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in R1 is a quaternary ammonium group, Y1 is a spacer chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, R2 and R3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: July 7, 2020
    Assignee: PDS Biotechnology Corporation
    Inventors: Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya N. Toney Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
  • Publication number: 20190374635
    Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of argumenting an immune response in a mammal, and methods of treating a diseases in a mammal utilizing the vaccine compositions.
    Type: Application
    Filed: March 28, 2019
    Publication date: December 12, 2019
    Inventors: Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
  • Publication number: 20190358319
    Abstract: The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+and CD4+T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.
    Type: Application
    Filed: August 6, 2019
    Publication date: November 28, 2019
    Inventors: Frank Bedu-Addo, Greg Conn, Siva K. Gandhapudi, Martin Ward, Jerold Woodward
  • Publication number: 20190358318
    Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid. The disclosure also provides methods of treating a disease in a mammal, methods of preventing a disease in a mammal, and methods of effecting antigen cross presentation to induce a humoral immune response and a cellular immune response in a mammal utilizing the vaccine compositions. Cross presentation of various antigens can be achieved by formulating the specific antigens with cationic lipids possessing adjuvant properties.
    Type: Application
    Filed: April 18, 2019
    Publication date: November 28, 2019
    Inventors: Frank Bedu-Addo, Eric Jacobson, Kenya Johnson
  • Publication number: 20190321321
    Abstract: Methods and compositions for modifying type I IFN signaling pathways in a subject comprising the administration a cationic lipid to the subject are provided. The cationic lipids comprise 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), N-1-(2,3-dioleoyloxy)-propyl-N,N,N-trimethyl ammonium chloride (DOTMA), 1,2-dioleoyl-sn-glycero-3-ethylphosphocholine (DOEPC), enantiomers and combinations thereof. The compositions may further comprise one or more antigenic components, wherein such components are autologous or nonautologous.
    Type: Application
    Filed: December 5, 2018
    Publication date: October 24, 2019
    Inventors: Frank Bedu-Addo, Greg Conn, Siva K. Gandhapudi, Martin Ward, Jerold Woodward
  • Publication number: 20190275145
    Abstract: The present disclosure provides vaccine formulations comprising at least one peptide antigen assembly and at least one adjuvant. The disclosure also provides methods of inducing an immune response in a mammal and methods of treating a disease in a mammal utilizing the vaccine formulations.
    Type: Application
    Filed: March 21, 2019
    Publication date: September 12, 2019
    Inventors: Frank Bedu-Addo, Gregory Conn, Eric Jacobson, Carol Mercer, Kenya Johnson
  • Patent number: 10286064
    Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of augmenting an immune response in a mammal, and methods of treating a disease in a mammal utilizing the vaccine compositions.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: May 14, 2019
    Assignees: PDS Biotechnology Corporation, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC. OF THE DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
  • Publication number: 20180353599
    Abstract: The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+ and CD4+ T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.
    Type: Application
    Filed: November 14, 2016
    Publication date: December 13, 2018
    Inventors: Frank Bedu-Addo, Greg Conn, Siva K. Gandhapudi, Martin Keough, Angela Mohs, Ritu Patel, Shweta Singh, Martin Ward, Jerold Woodward
  • Publication number: 20180221475
    Abstract: Methods and compositions for altering the microenvironment of a tumor are provided. The methods comprise reducing the population of tumor-residing immune suppressive regulatory T-cells, increasing the population of tumor lysing T-cells (such as CD8+ T-cells) and improving the efficacy of cancer immunotherapy. The compositions comprise the use of cationic lipids optionally combined with autologous antigens, non-autologous antigens, or tumor-associated antigens.
    Type: Application
    Filed: October 5, 2017
    Publication date: August 9, 2018
    Inventors: Frank Bedu-Addo, Greg Conn, Siva K. Gandhapudi, Martin Ward, Jerold Woodward
  • Publication number: 20180094032
    Abstract: Novel human papillomovirus immunogenic compositions and methods of use thereof are provided. The compositions comprise unique combinations of multi-epitope peptide sequences specifically selected and designed to be effectively processed and cross-presented to T-cells. The peptides utilized in the compositions display high levels of binding with HLA-supertypes. The immunogenic compositions are broadly applicable to large proportions of target populations. The compositions comprise adjuvants such as cationic lipids.
    Type: Application
    Filed: October 4, 2017
    Publication date: April 5, 2018
    Inventors: Frank Bedu-Addo, Greg Conn, Martin Ward, Jerold Woodward
  • Publication number: 20180015114
    Abstract: A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in R1 is a quaternary ammonium group, Y1 is a spacer chosen from a hydrocarbon chain, an ester, a ketone, and a peptide, C* is a chiral carbon, R2 and R3 are independently chosen from a saturated fatty acid, an unsaturated fatty acid, an ester-linked hydrocarbon, phosphor-diesters, and combinations thereof.
    Type: Application
    Filed: September 12, 2017
    Publication date: January 18, 2018
    Inventors: Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya N. Toney Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
  • Patent number: 9789129
    Abstract: Compositions and methods for treating immune cells and activating immune responses are disclosed. The compositions comprise one or more optically active chiral cationic lipids.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: October 17, 2017
    Assignee: PDS Biotechnology Corporation
    Inventors: Elizabeth Ann Vasievich, Weihsu Claire Chen, Kenya Toney Johnson, Gregory Conn, Frank Bedu-Addo, Leaf Huang
  • Publication number: 20150250872
    Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid. The disclosure also provides methods of treating a disease in a mammal, methods of preventing a disease in a mammal, and methods of effecting antigen cross presentation to induce a humoral immune response and a cellular immune response in a mammal utilizing the vaccine compositions. Cross presentation of various antigens can be achieved by formulating the specific antigens with cationic lipids possessing adjuvant properties.
    Type: Application
    Filed: September 23, 2013
    Publication date: September 10, 2015
    Inventors: Frank BEDU-ADDO, Eric JACOBSON, Kenya JOHNSON
  • Publication number: 20150132340
    Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of augmenting an immune response in a mammal, and methods of treating a disease in a mammal utilizing the vaccine compositions.
    Type: Application
    Filed: June 13, 2013
    Publication date: May 14, 2015
    Inventors: Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
  • Publication number: 20150110823
    Abstract: The present disclosure provides vaccine formulations comprising at least one peptide antigen assembly and at least one adjuvant. The disclosure also provides methods of inducing an immune response in a mammal and methods of treating a disease in a mammal utilizing the vaccine formulations.
    Type: Application
    Filed: September 12, 2012
    Publication date: April 23, 2015
    Applicant: PDS BIOTECHNOLOGY CORPORATION
    Inventors: Frank Bedu-Addo, Gregory Conn, Eric Jacobson, Carol Mercer, Kenya Johnson
  • Publication number: 20150093410
    Abstract: The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.
    Type: Application
    Filed: November 3, 2014
    Publication date: April 2, 2015
    Inventors: Weihsu CHEN, Weili YAN, Kenya JOHNSON, Gregory CONN, Frank BEDU-ADDO, Leaf HUANG
  • Patent number: 8877206
    Abstract: The present invention provides compositions and methods for stimulating an immune response using cationic lipids alone or in combination with antigens.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: November 4, 2014
    Assignee: PDS Biotechnology Corporation
    Inventors: Weihsu Chen, Weili Yan, Kenya Toney, Gregory Conn, Frank Bedu-Addo, Leaf Huang